Menu
Search Close

News

Nottingham Technology Grant

06th January 2014

Scancell Holdings Plc, (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that it has received a Nottingham Technology Grant Fund (”N’Tech”) of £80,000 from Nottingham City Council. Funded by the Government’s Regional Growth Fund, the grants from N’Tech are awarded mainly to small and medium-sized companies to support business growth and expansion in the Greater Nottingham area. Scancell will use the funds to secure additional staff to develop its groundbreaking new Moditope® technology platform.

Richard Goodfellow, Joint CEO of Scancell, said: “We are delighted to receive this additional funding from Nottingham City Council. This funding will allow us to expand our skill base and boost our productivity at this important juncture in the Company’s history."

For Further Information:

 

Dr Richard Goodfellow, Joint CEO

Professor Lindy Durrant, Joint CEO

Scancell Holdings Plc

Scancell Holdings Plc

+ 44 (0) 20 7831 3113

 Camilla Hume/Stephen Keys

 Cenkos Securities plc

 + 44 (0) 20 7397 8900

     

Mo Noonan/Simon Conway

FTI Consulting

+ 44 (0) 20 7831 3113

 

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.  Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and has just completed Phase 1/2 clinical trials which demonstrated that SCIB1 produced a melanoma-specific immune response and promising survival trend.  A further higher dose study of SCIB1 will take place during 2014.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity.  The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future

Webcasts, Interviews and Media Coverage

Scancell welcomes strategic new investor Vulpes Life Sciences Fund

Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.

The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.

Thu, 13 Jun 2019 09:53:00

Scancell raises £3.9mln to advance immunotherapy product pipeline

“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”

Thu, 13 Jun 2019 06:31:00

Scancell exploring new frontiers in cancer research

Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology

Mon, 20 May 2019 09:51:00